ReviewHematology. American Society of Hematology. Education Program2020
Platelet transfusion refractoriness: how do I diagnose and manage?
Review in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2022Pooled it
- A quasi-experimental study evaluating the efficacy of crossmatch-matched platelet transfusions in hemato-oncology patients with suspected alloimmune platelet refractoriness: A single-centre experience.Transfusion medicine (Oxford, England) · 2026Trial
- Diagnosis and management of post-transfusion purpura in the acute trauma setting: A case report.Transfusion · 2026Article
- Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness.Transfusion · 2026Article
- Immune-mediated platelet refractoriness: Mechanisms, diagnostics, and therapeutic breakthroughs.Transfusion medicine (Oxford, England) · 2026Review
- Laboratory Assessment and Clinical Outlook forAnnals of laboratory medicine · 2026Review
- Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness.Haematologica · 2026Article
- Targeting macrophages prevents alloantibody-mediated platelet clearance in a murine model of transfusion refractoriness.Blood advances · 2026Article
- Macrophages are key mediators of platelet refractoriness.Blood advances · 2026Article
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Emergency Cholecystectomy for Gangrenous Acute Cholecystitis with Profound Thrombocytopenia: Immune Thrombocytopenia Diagnosed Postoperatively.Surgical case reports · 2026Article
- Demand for human leukocyte antigen or human platelet antigen-selected platelets: An observational study at Canadian Blood Services.Transfusion · 2026Observational
- Personalized management of platelet transfusion refractoriness: risk factors, cross-matching, and IVIG strategies.Frontiers in medicine · 2026Article
- When it's not Glanzmann thrombasthenia or Bernard-Soulier syndrome: diagnosing other qualitative platelet disorders.Hematology. American Society of Hematology. Education Program · 2025Review
- Genetics by genetic algorithm: Defining an ideal platelet donor population to support patients with HLA-mediated alloimmune refractoriness.Transfusion · 2025Article
- Remimazolam-Based Anesthetic Management in a Patient with Severe Aortic Stenosis and Myelodysplastic Syndrome-Related Thrombocytopenia: A Case Report.Journal of clinical medicine · 2025Article
- Clinical and Molecular Spectrum of MYH9-Thrombocytopenia: Insights from a Single Centric Pediatric Cohort.Children (Basel, Switzerland) · 2025Article
- Postresuscitation platelet transfusion in major trauma patients.Transfusion · 2025Article
- Incidence, kinetics, and clinical impact of thrombocytopenia in venovenous ECMO: insights from the multicenter observational PROTECMO study.Critical care (London, England) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet refractoriness continues to be a problem for thrombocytopenic patients because the risk of a major spontaneous or life-threatening bleed significantly increases when platelet counts drop below 10 × 109/L. The majority of patients have nonimmune causes driving the refractoriness, such as bleeding, medications, or diffuse intravascular coagulation; however, this article is dedicated to the diagnosis and support of patients with immune-based platelet refractoriness. Antibodies to class I HLA molecules (A and B alleles) are responsible for most immune-based refractory cases, with antibodies to platelet antigens seen much less frequently. Patients may be supported with either crossmatch-compatible or HLA-matched/compatible platelet units. When trying to select HLA units it can be difficult to find a perfect "4 of 4" match for the patient's class IA and IB alleles. In these cases, it is better to use the antibody specificity prediction method, which identifies compatible units that lack antigens recognized by the patient's anti-HLA antibodies. For an algorithmic approach to the patient with platelet refractoriness, see Visual Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.